DiaGenic

NEW YORK (GenomeWeb News) – Norwegian biomarker diagnostics firm DiaGenic today announced the initiation of a cost reduction program, which includes the elimination of an undisclosed number of jobs.

Norwegian molecular diagnostic developer DiaGenic said this week that it has adopted Life Technologies' recently launched QuantStudio Dx platform to further enable development of its pipeline of multi-biomarker blood-based molecular assays for Alzheimer's disease.

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.

DiaGenic said this week that CEO Erik Christensen has resigned.
Christensen will "continue to provide consultative support to the company on partner interactions, licensing and other business activities," DiaGenic said in a statement.

The story has been updated to clarify the nature of the test in the headline.
By a GenomeWeb staff reporter

After the split, the Norwegian firm had about 27 million shares of common stock outstanding.

The firm terminated its market-making contract with the investment firm, as trading of its stock has been "very high."

The firms will use DiaGenic's gene expression technology in a study to identify biomarkers related to patients who progress from mild cognitive impairment to Alzheimer's.

Pages

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.